Boespflug O, Godfraind C, Tardieu M
Laboratoire de Neurovirologie, INSERM U 56, Hôpital de Bicêtre, France.
J Neuroimmunol. 1989 Jan;21(1):49-57. doi: 10.1016/0165-5728(89)90158-6.
The effects of cyclosporin A (CsA) on neuropathological lesions induced by a chronic viral infection have been tested in the experimental model of the mouse hepatitis virus 3 (MHV3) infection. Daily injections of CsA (50 mg/kg) inhibited the expression of the MHV3-induced ependymitis, meningitis, hydrocephalus and vasculitis. The effect was preserved even if CsA treatment was initiated 15 days after virus infection but was lost if CsA treatment was given later on or for a shorter period of time. Viral titers in brains of chronically infected mice were not affected by CsA treatment. During the first week following MHV3 infection, CsA treatment increased both the percentage of acute death (31 vs. 10%) and the viral titers in brain and liver of infected mice. In this model, the timing of CsA treatment appeared critical for the balance between its beneficial effect on CNS lesions and the risk of increased acute mortality.
在小鼠肝炎病毒3型(MHV3)感染的实验模型中,已对环孢素A(CsA)对慢性病毒感染所致神经病理损伤的影响进行了测试。每日注射CsA(50毫克/千克)可抑制MHV3诱导的室管膜炎、脑膜炎、脑积水和血管炎的表达。即便在病毒感染15天后开始CsA治疗,该效果仍得以维持,但如果CsA治疗开始时间更晚或持续时间更短,则该效果消失。慢性感染小鼠大脑中的病毒滴度不受CsA治疗的影响。在MHV3感染后的第一周,CsA治疗增加了急性死亡百分比(31%对10%)以及感染小鼠大脑和肝脏中的病毒滴度。在该模型中,CsA治疗的时机对于其对中枢神经系统病变的有益作用与急性死亡率增加风险之间的平衡似乎至关重要。